Skip to Content

MONDAY, 22 OCTOBER 2018, 10:16


Roche lands Tecentriq trial win, still trails Merck in lung cancer

Today at 09:22 AM, via Reuters

Roche’s Tecentriq plus chemotherapy boosted lung cancer patients’ survival by nearly five months, study data released on Monday showed, underscoring benefits of the Swiss group’s immunotherapy but still leaving it trailing a rival’s drug.

South Africans Urged to Regularly Check Blood Pressure

Today at 09:00 AM, via eHealth News

Commonly referred to as ‘the silent killer’, high blood pressure (or hypertension) often has no symptoms and greatly increases the risk of heart attack and stroke.

South Africa has the highest prevalence of hypertension in southern Africa, and also has the largest number of people whose blood pressure is still not controlled, even while on treatment.

With National Stroke Week (28 October – 3...

FibriCheck App Gets FDA Certification

Today at 09:00 AM, via eHealth News

FibriCheck, an mHealth app developed by Belgian startup Qompium, has become the world’s first FDA approved app capable of detecting atrial fibrillation, and other heart rhythm disorders, using only an optical signal originating from a non-medical device such as a smartphone.

Atrial fibrillation is a disorder that affects one out of four adults and increases the likelihood of having a...

Could diet affect breast cancer risk?

Today at 07:27 AM, via Health24

Like the human gut, the breast gland has a “microbiome” that’s influenced by diet, new animal research suggests.

Merck KGaA says might strike partnership deal this year

Yesterday at 21:12 PM, via Reuters

German drugmaker Merck KGaA might agree partnership deals to jointly develop two of its most promising experimental medicines with a rival as early as this year, but more likely in 2019, its drug research and development chief said on Sunday.

AstraZeneca’s Lynparza shown to put brakes on ovarian cancer

Yesterday at 16:33 PM, via Reuters

An AstraZeneca drug that blocks a cancer cell’s ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.

Roche takes on Loxo, Bayer in gene-defined cancer class

Yesterday at 11:22 AM, via Reuters

Roche’s entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

  1. Pages:
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. ...
  8. 17